Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00157898
NCT00157898
Completed
Phase 4

A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus it's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults

Merck Sharp & Dohme LLC0 sites134 target enrollmentJanuary 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsComplicated Intra-abdominal Infection
DrugsMK0826; ertapenem sodiumComparator: ceftriaxone + metronidazole

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Complicated Intra-abdominal Infection
Sponsor
Merck Sharp & Dohme LLC
Enrollment
134
Primary Endpoint
Favorable clinical response at 7-14 days after treatment
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This was a prospective, randomized, controlled, open, and multi-center trial conducted to compare the clinical efficacy and safety of ertapenem with it's comparator before or following adequate surgical management of complicated intra-abdominal infection.

Registry
clinicaltrials.gov
Start Date
January 2004
End Date
September 2004
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Males or females between the ages of 18 and 75 who have complicated intra-abdominal infection.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Favorable clinical response at 7-14 days after treatment

Secondary Outcomes

  • Favorable microbiologic response at 7-14 days after treatment

Similar Trials

Not yet recruiting
Phase 4
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLRelapsed/Refractory AML
NCT06763666Nanfang Hospital, Southern Medical University172
Active, not recruiting
Not Applicable
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous LevelsCervical Disc Disease
NCT04564885Spineart USA300
Active, not recruiting
Not Applicable
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc DiseaseCervical Disc Disease
NCT04520776Spineart USA284
Completed
Not Applicable
Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip AugmentationAbnormal Lip
NCT04917588Croma-Pharma GmbH114
Completed
Phase 4
Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)Primary Adrenal InsufficiencySecondary Adrenal Insufficiency
NCT02277587University of Roma La Sapienza89